Dhileep holds a Ph.D. in Organic Chemistry from the University of Utah, US in 1995 and a Master's degree from Indian Institute of Technology Bombay. His Ph.D degree was focused on total synthesis of anti-tumor antibiotic natural product rhizoxin D and the break through discovery of BITIP catalyzed asymmetric carbon-carbon bond forming reactions.

After a short Post-doctoral stint with Professor Gary Keck, he joined the process research group in Bristol-Myers Squib (BMS). At BMS he was instrumental in discovering the commercial route for anti-viral NCE "Entecavir". In 1999, he moved to Sepracor Inc., where his group contributed to number of fast track Improved Chemical Entities (ICE) projects. In late 2002, he joined Boehringer-Ingelheim (BI), where he was most recently served as Director for Process Research at R&D head quarter in USA. At BI, he held Management and Scientific responsibility of Process Chemistry group, Chemical Catalysis/Automation, Radio Synthesis group and API Crystallization group. His R&D responsibilities include design and synthesis of NCE based cGMP API's from multi gram to > 100 Kg for pre-clinical, clinical and formulation development. His research interest includes Discovery and Development of patent free, economical, green synthesis of API using traditional and modern approaches.

He has more than 60 Publications, Patents and Book Chapters. He has delivered many invited lectures in academic institutions and international professional conferences. Most recently, he served in the judging panel for the US Presidential Green Chemistry challenge award.

At present, Dr. Dhileep Krishnamurthy holds Vice President – Chemistry position and he is heading the chemistry function at IPDO, Dr. Reddy’s Laboratories, Hyderabad.

Dr. Dhileep Krishnamurthy's Abstract for IGCW 2011